Tango Therapeutics, Inc. — Investor Relations & Filings

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing a new generation of precision oncology medicines. The company's approach is centered on the principle of synthetic lethality, a genetic strategy to target cancer vulnerabilities. By utilizing its proprietary drug discovery platform, which integrates CRISPR technology, Tango identifies novel drug targets and develops therapies for genetically defined patient populations with unmet medical needs. The company's pipeline is designed to deliver transformative medicines that take direct aim at specific tumors, with the goal of expanding the reach of genetically targeted cancer therapies.